Arkolith/Insider Trading/CRBP/Form 4

Jenkins John Kenneth

DirectorCorbus Pharmaceuticals Holdings, Inc. (CRBP) · full profile →Form 4 · filed Jun 2, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$20K
Net Open-Market Flow
-$20K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 30, 2025Grant(A)5K—$05K
May 30, 2025Sell(S)3K$7.35$20K33

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 30, 2025Grant(A)16K—$016K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-080311) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML